Skip to main content

Atrium Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

RNA$8.34+0.2%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and per share amounts)

March 31,December 31,
20262025
Assets
Current assets:
Cash and cash equivalents$267,849$—
Collaboration receivable15,000—
Prepaid assets2,5781,535
Other current assets1381,310
Total current assets285,5652,845
Restricted cash415—
Property and equipment, net4,3372,724
Right-of-use asset2,0432,784
Total assets$292,360$8,353
Liabilities and Stockholders’ Equity/Former Parent Deficit
Current liabilities:
Accounts payable$807$4,398
Accrued liabilities6,9838,945
Accrued compensation2,0913,147
Lease liabilities2,6803,672
Deferred revenue, current portion9,34421,639
Total current liabilities21,90541,801
Deferred revenue, net of current portion36,35128,691
Other long-term liabilities—574
Total liabilities58,25671,066
Commitments and contingencies
Stockholders’ equity/ Former Parent's deficit:
Preferred stock, $0.001 par value: 40,000,000 shares authorized; no shares issued and outstanding——
Common stock, $0.001 par value: 400,000,000 shares authorized; 17,105,643 shares issued and outstanding as of March 31, 2026, and no shares authorized, issued, or outstanding as of December 31, 202516—
Additional paid-in capital221,960—
Retained earnings12,128—
Net Investment from Former Parent—(62,713)
Total stockholders’ equity/Former Parent’s deficit234,104(62,713)
Total liabilities and Stockholders’ equity/Former Parent’s deficit$292,360$8,353
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.